Marco Meglio, Editor for NeurologyLive, has been with the team since October 2019. Follow him on Twitter @marcomeglio1 or email him at mmeglio@neurologylive.com
Age at MS Disease Onset Affects Pathophysiology, Gray and White Matter
January 14th 2022The authors noted that the findings indirectly support the use of highly effective disease-modifying treatments from the early stages of disease in those with pediatric-onset MS, even in the absence of persistent physical disability.
New Data Boosts Efficacy Profile of gammaCore nVNS Device for Migraine Prevention
January 11th 2022The noninvasive vagus nerve stimulation device showed results consistent with what had been previously observed in the literature, with a particular benefit observed for those who have migraine with aura.
Xywav Oral Solution Shows Continued Efficacy in Idiopathic Hypersomnia
January 7th 2022The Jazz Pharmaceuticals’ product, which was FDA approved in August 2021, demonstrated clinically meaningful differences compared with placebo on several secondary end points, including impression of change scales and various and questionnaires.
Need for Guidelines on Migraine in Emergency Department Settings
January 6th 2022Anne-Maree Kelly, MD, director, Joseph Epstein Center for Emergency Medicine Research, detailed the complexities of presenting migraine in the emergency department and why consensus international/national guidelines tailorable to the capabilities of institutions is necessary.
MS Disease-Modifying Therapy Discontinuation Associated With Disability Progression
January 5th 2022DMT discontinuation resulted with new disability worsening and/or progression in previously stable patients with relapsing-remitting MS and particularly in patients with previously stable secondary progressive MS.
Antiseizure Medications Display Mortality Differences in Poststroke Epilepsy
January 4th 2022The study authors concluded that while there are differences in survival between specific ASMs, lamotrigine and levetiracetam appear to be reasonable first-line treatment options for patients with poststroke epilepsy.
DAPT Approach With Ticagrelor, Clopidogrel Demonstrate Efficacy Over Aspirin Alone
December 21st 2021Although similar in reducing the risk of recurrent stroke, the use dual antiplatelet therapy with clopidogrel and aspirin was associated with a decreased risk of functional disability compared with ticagrelor and aspirin.